Ionis Pharmaceuticals, Inc. Stock

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-21 EDT Pre-market 07:07:50
41.83 USD +2.50% Intraday chart for Ionis Pharmaceuticals, Inc. 42.95 +2.68%
Sales 2024 * 598M 818M Sales 2025 * 767M 1.05B Capitalization 6.1B 8.34B
Net income 2024 * -573M -784M Net income 2025 * -520M -711M EV / Sales 2024 * 9.64 x
Net cash position 2024 * 335M 459M Net Debt 2025 * 72.35M 98.95M EV / Sales 2025 * 8.05 x
P/E ratio 2024 *
-11 x
P/E ratio 2025 *
-12.7 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Assessed data
Dynamic Chart
ANALYST RECOMMENDATIONS : Home Depot, Apple, Micron Technology, Anglo American, United Utilities... Our Logo
Ionis Pharmaceuticals Insider Sold Shares Worth $644,640, According to a Recent SEC Filing MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen?s Genetic Medicines & RNA Summit, Jun-20-2024 03:30 PM
Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific MT
Ionis Pharmaceuticals, Inc. Announces Expand Licensing Agreement with Otsuka Pharmaceutical Co., Ltd CI
Investors need more time to assess Fed comments Our Logo
Bernstein Upgrades Ionis Pharmaceuticals to Market Perform From Underperform, Adjusts Price Target to $44 From $37 MT
ANALYST RECOMMENDATIONS : Adobe, Bank of America, Boeing, Nvidia, Wise... Our Logo
Transcript : Ionis Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 through Jun-13-2024
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema MT
Transcript : Ionis Pharmaceuticals, Inc. - Special Call
Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Sector Update: Health Care Stocks Ease Thursday Afternoon MT
More news
1 day+2.50%
1 week+2.90%
Current month+11.34%
1 month+10.08%
3 months-2.08%
6 months-18.28%
Current year-17.32%
More quotes
1 week
40.15
Extreme 40.15
42.13
1 month
35.95
Extreme 35.95
42.13
Current year
35.95
Extreme 35.95
54.44
1 year
35.95
Extreme 35.95
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 12-06-30
Founder 62 89-01-09
Director of Finance/CFO 62 00-04-30
Members of the board TitleAgeSince
Chairman 72 14-02-02
Founder 62 89-01-09
Director/Board Member 70 19-06-09
More insiders
Date Price Change Volume
24-06-21 41.83 +2.50% 1,710,423
24-06-20 40.81 +0.42% 835,632
24-06-18 40.64 -0.29% 950,524
24-06-17 40.76 +0.27% 795,265

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
41.83 USD
Average target price
58.04 USD
Spread / Average Target
+38.74%
Consensus